Severe Hemophilia A Clinical Trial
Official title:
A-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia A
The primary objectives of this study are: to evaluate the safety and tolerability of rFVIIIFc administered as a prophylaxis (Arm 1), weekly (Arm 2), on-demand (Arm 3), and surgical treatment regimen; to evaluate the efficacy of the rFVIIIFc tailored prophylaxis regimen (Arm 1); to evaluate the efficacy of rFVIIIFc administered as an on-demand (Arm 3) and surgical treatment regimen. The secondary objectives of this study are: to characterize the PK profile of rFVIIIFc and compare the PK of rFVIIIFc with the currently marketed product, Advate®; to characterize the range of dose and schedules required to adequately prevent bleeding in a prophylaxis regimen, maintain hemostasis in a surgical setting, or to treat bleeding episodes in an on-demand, weekly treatment, or prophylaxis setting.
Participants are assigned to one of three treatment regimens: 1) a tailored prophylaxis regimen, 2) a weekly dosing regimen, or 3) an on-demand regimen. Treatment continued for 28 (±2) to 52 (±2) weeks. PK assessments for all participants are conducted on varying schedules, according to participants' group assignments. Additionally, two subgroups are defined. One subgroup of participants undergo PK profiling with a single dose of the comparator Advate®. A second subgroup consists of participants from any of the treatment arms that required surgery during the study. Depending upon country location, participants might have the option of continuing treatment within study 8HA01EXT (NCT01454739). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01051544 -
Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive
|
N/A | |
| Completed |
NCT02172950 -
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT01051076 -
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
|
N/A | |
| Completed |
NCT03376516 -
Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
|
Phase 3 | |
| Not yet recruiting |
NCT06136507 -
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT02083965 -
Pharmacokinetics of rFVIIIFc at Two Vial Strengths
|
Phase 1 | |
| Completed |
NCT01085344 -
Canadian Hemophilia Prophylaxis Study
|
Phase 4 | |
| Completed |
NCT04864743 -
A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
|
Phase 1 | |
| Completed |
NCT01341912 -
Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)
|
Phase 3 | |
| Completed |
NCT01125813 -
Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
|
Phase 3 | |
| Active, not recruiting |
NCT05181618 -
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
|
Phase 4 | |
| Terminated |
NCT04046848 -
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
|
Phase 1/Phase 2 | |
| Completed |
NCT06137092 -
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
|
Phase 3 | |
| Terminated |
NCT01405742 -
Hemophilia Adult Prophylaxis Study
|
Phase 3 | |
| Active, not recruiting |
NCT04431726 -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
|
Phase 3 | |
| Recruiting |
NCT05935358 -
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
|
Phase 4 | |
| Completed |
NCT01712438 -
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
|
Phase 3 | |
| Recruiting |
NCT06142552 -
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
|
Phase 3 | |
| Completed |
NCT02954575 -
Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
|
Phase 3 | |
| Completed |
NCT01027377 -
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
|
Phase 1 |